CA2344677A1 - Improving memory by the administration of .delta.5-androstene-3.beta.-ol-7,17-dione and 3.beta. esters thereof - Google Patents
Improving memory by the administration of .delta.5-androstene-3.beta.-ol-7,17-dione and 3.beta. esters thereof Download PDFInfo
- Publication number
- CA2344677A1 CA2344677A1 CA002344677A CA2344677A CA2344677A1 CA 2344677 A1 CA2344677 A1 CA 2344677A1 CA 002344677 A CA002344677 A CA 002344677A CA 2344677 A CA2344677 A CA 2344677A CA 2344677 A1 CA2344677 A1 CA 2344677A1
- Authority
- CA
- Canada
- Prior art keywords
- steroid
- beta
- administering
- androstene
- dione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 title claims abstract description 20
- 230000015654 memory Effects 0.000 title claims abstract description 16
- 150000002148 esters Chemical class 0.000 title claims abstract description 7
- 241000124008 Mammalia Species 0.000 claims abstract description 11
- 230000001771 impaired effect Effects 0.000 claims abstract description 3
- 150000003431 steroids Chemical class 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 21
- 230000037406 food intake Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000007787 long-term memory Effects 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 11
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 11
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 11
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 11
- 229960002646 scopolamine Drugs 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 7
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical class C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 7
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 6
- 229960002847 prasterone Drugs 0.000 description 6
- 239000002243 precursor Substances 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 238000012347 Morris Water Maze Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- NJPPVKZQTLUDBO-UHFFFAOYSA-N novaluron Chemical compound C1=C(Cl)C(OC(F)(F)C(OC(F)(F)F)F)=CC=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F NJPPVKZQTLUDBO-UHFFFAOYSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- -1 douch Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/174,235 US6153606A (en) | 1998-10-16 | 1998-10-16 | Memory enhancement by the administration of Δ5-androstene-3β-ol-7,17-dione and 3β esters thereof |
| US09/174,235 | 1998-10-16 | ||
| PCT/US1999/024076 WO2000023080A1 (en) | 1998-10-16 | 1999-10-13 | IMPROVING MEMORY BY THE ADMINISTRATION OF Δ5-ANDROSTENE-3β-OL-7,17-DIONE AND 3β ESTERS THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2344677A1 true CA2344677A1 (en) | 2000-04-27 |
Family
ID=22635389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002344677A Abandoned CA2344677A1 (en) | 1998-10-16 | 1999-10-13 | Improving memory by the administration of .delta.5-androstene-3.beta.-ol-7,17-dione and 3.beta. esters thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6153606A (enExample) |
| EP (1) | EP1123100B1 (enExample) |
| JP (1) | JP2002527481A (enExample) |
| AT (1) | ATE289819T1 (enExample) |
| CA (1) | CA2344677A1 (enExample) |
| DE (1) | DE69923988T2 (enExample) |
| WO (1) | WO2000023080A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6153606A (en) * | 1998-10-16 | 2000-11-28 | Humanetics Corporation | Memory enhancement by the administration of Δ5-androstene-3β-ol-7,17-dione and 3β esters thereof |
| US6667299B1 (en) * | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
| US7553829B2 (en) * | 2000-11-30 | 2009-06-30 | Humanetics Corporation | Treatment of chronic fatigue syndrome and fibromyalgia syndrome |
| US6399085B1 (en) | 2001-03-05 | 2002-06-04 | Humanetics Corporation | Method of moisturizing the skin by the topical application of Δ5-androstene-3β-ol-7,17 dione and metabolizable precursors thereof |
| US6399084B1 (en) | 2001-03-05 | 2002-06-04 | Humanetics Corporation | Method for diminishing wrinkles and fine lines of the skin by the topical application of Δ5-androstene-3β-ol-7, 17 dione and metabolizable precursors thereof |
| US6465446B1 (en) | 2001-03-12 | 2002-10-15 | John C. Dykstra | Treatment of dermatitis by the topical application of Δ5-androstene-3β-ol-7,17 dione and metabolizable precursors thereof |
| US8084446B2 (en) * | 2005-04-26 | 2011-12-27 | Eric Marchewitz | Use of DHEA derivatives for enhancing physical performance |
| ATE487488T1 (de) | 2006-03-09 | 2010-11-15 | Cambridge Entpr Ltd | Neuartige antibiotische zusammensetzungen |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4791099A (en) * | 1984-10-29 | 1988-12-13 | Chaovanee Aroonsakul | Method of treatment for central nervous system diseases such as Alzheimer's's disease |
| US4812447A (en) * | 1985-10-22 | 1989-03-14 | City Of Hope | Method for the treatment of nervous system degeneration |
| US5424463A (en) * | 1990-08-29 | 1995-06-13 | Humanetics Corporation | Δ5-androstenes useful for promoting weight maintenance or weight loss and treatment process |
| US5292730A (en) * | 1990-08-29 | 1994-03-08 | Humanetics Corporation | Modulation of immune system with Δ5-androstenes |
| US5641766A (en) * | 1990-08-29 | 1997-06-24 | Humanetics Corporation | UP-regulation of immune system with Δ 5-Androstenes |
| ATE227992T1 (de) * | 1990-08-29 | 2002-12-15 | Humanetics Corp | Behandlungsverfahren zur förderung des gewichtsverlustes unter verwendung eines substituierten delta-5-androstens |
| US5807848A (en) * | 1990-08-29 | 1998-09-15 | Humanetics Corporation | Use of dehydroepeiandrosterone-3-carboxylates to control body weight |
| US5707983A (en) * | 1990-08-29 | 1998-01-13 | Humanetics Corporation | Treatment of alzheimer's disease and modulation of immune system with Δ5-androstenes |
| US5585371A (en) * | 1990-08-29 | 1996-12-17 | Humanetics Corporation | Treatment of immune system with Δ5-androstenes |
| CA2148373A1 (en) * | 1993-09-02 | 1995-03-09 | Henry A. Lardy | Delta 5-androstenes useful for promoting weight maintenance or weight loss and treatment process |
| US5420028A (en) * | 1993-10-13 | 1995-05-30 | Northeastern Ohio Universities | Truncated human cholesterol 7α-hydroxylase, method of production and use thereof |
| GB9421093D0 (en) * | 1994-10-19 | 1994-12-07 | Univ Edinburgh | Hippocampus-associated proteins, DNA sequences coding therefore and uses thereof |
| US5556847A (en) * | 1994-10-27 | 1996-09-17 | Duquesne University Of The Holy Ghost | Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors |
| CA2250874A1 (en) * | 1996-04-09 | 1997-10-16 | Btg International Limited | Use of 7 alpha-substituted steroids to treat neuropsychiatric, immune or endocrine disorders |
| US6153606A (en) * | 1998-10-16 | 2000-11-28 | Humanetics Corporation | Memory enhancement by the administration of Δ5-androstene-3β-ol-7,17-dione and 3β esters thereof |
-
1998
- 1998-10-16 US US09/174,235 patent/US6153606A/en not_active Expired - Lifetime
-
1999
- 1999-10-13 WO PCT/US1999/024076 patent/WO2000023080A1/en not_active Ceased
- 1999-10-13 EP EP99954931A patent/EP1123100B1/en not_active Expired - Lifetime
- 1999-10-13 JP JP2000576854A patent/JP2002527481A/ja active Pending
- 1999-10-13 CA CA002344677A patent/CA2344677A1/en not_active Abandoned
- 1999-10-13 AT AT99954931T patent/ATE289819T1/de not_active IP Right Cessation
- 1999-10-13 DE DE69923988T patent/DE69923988T2/de not_active Expired - Fee Related
-
2000
- 2000-11-01 US US09/704,495 patent/US6489313B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ATE289819T1 (de) | 2005-03-15 |
| JP2002527481A (ja) | 2002-08-27 |
| US6489313B1 (en) | 2002-12-03 |
| DE69923988D1 (de) | 2005-04-07 |
| EP1123100B1 (en) | 2005-03-02 |
| EP1123100A1 (en) | 2001-08-16 |
| EP1123100A4 (en) | 2001-12-19 |
| DE69923988T2 (de) | 2006-04-06 |
| WO2000023080A1 (en) | 2000-04-27 |
| US6153606A (en) | 2000-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5292730A (en) | Modulation of immune system with Δ5-androstenes | |
| WO2004062606A2 (en) | Method of achieving accelerated fat loss by administration of a fat loss accelerating agent to a dieting mammal | |
| US5585371A (en) | Treatment of immune system with Δ5-androstenes | |
| US5461042A (en) | Regulation of the immune system | |
| US5641766A (en) | UP-regulation of immune system with Δ 5-Androstenes | |
| US6153606A (en) | Memory enhancement by the administration of Δ5-androstene-3β-ol-7,17-dione and 3β esters thereof | |
| US5641768A (en) | 5-androstene 3β, 17β diol for treatment | |
| US5707983A (en) | Treatment of alzheimer's disease and modulation of immune system with Δ5-androstenes | |
| CA2276783A1 (en) | Use of .delta.5 androstenes in the treatment of hiv wasting syndrome | |
| JP4450435B2 (ja) | Ｐｍｓおよび不安の症状を緩和する、ｖｎｏにおける神経化学刺激物質としてのステロイド | |
| Oravec et al. | Management of diabetes insipidus in pregnancy | |
| Kelly et al. | Iatrogenic Cushing's syndrome | |
| US7199116B2 (en) | Method of modulating the basal metabolic rate of a dieting mammal by administration of a metabolic modulating agent to the dieting mammal | |
| US7553829B2 (en) | Treatment of chronic fatigue syndrome and fibromyalgia syndrome | |
| WO2002024205A1 (en) | TREATMENT OF INFLAMMATORY BOWEL DISEASE BY THE ADMINISTRATION OF Δ5-ANDROSTENE-3β-OL-7,17 DIONE AND METABOLIZABLE PRECURSORS THEREOF | |
| US6794374B1 (en) | Use of Δ5-androstene-3β-OL7,17-dione in the treatment of arthritis | |
| WO1999025192A1 (en) | USE OF Δ5-ANDROSTENE-3β-OL-7,17-DIONE IN THE TREATMENT OF ARTHRITIS | |
| US20060135499A1 (en) | Method of achieving accelerated weight loss by administration of a weight loss accelerating agent to a dieting mammal | |
| US20060217357A1 (en) | Method of achieving accelerated fat loss by administration of a fat loss accelerating agent to a dieting mammal | |
| US6897239B1 (en) | Use of misoprostol and/or metabolites of misoprostol for treating sexual dysfunction in women | |
| RU2162323C1 (ru) | Способ лечения гестоза беременных | |
| Teter | Treatment of endocrine impotence | |
| Gaster | The Porn Industry | |
| JPH08509245A (ja) | 乾癬の治療におけるセルレチドジエチルアミン塩の使用 | |
| JPH0623110B2 (ja) | シスタノサイド類を有効成分とするストレスによる機能障害改善剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |